VENTYX BIOSCIENCES, INC. VTYX 深 沪
等待开盘 11-06 09:30:00 美东时间
9.00
+0.910
+11.25%
华盛通- 最 高9.23
- 今 开8.59
- 成交量 349.12万股
- 最 低 8.27
- 昨 收 8.09
- 总市值 6.42亿
- 52周最高 9.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.783
- 委 比 98.68%
- 总股本 7130.85万
- 历史最高 47.2508
- 量 比 0.92
- 振 幅 11.87%
- 历史最低 0.783
- 每 手 1
- 风险率 1.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
今天 09:55
HC Wainwright & Co. Upgrades Ventyx Biosciences to Buy, Announces $18 Price Target
HC Wainwright & Co. analyst Emily Bodnar upgrades Ventyx Biosciences (NASDAQ:VTYX) from Neutral to Buy and announces $18 price target.
11-05 19:24
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
美股牛股 | VTYX大涨71%！新药研究取得积极结果；SEV转型为公益公司，涨近58%
VTYX大涨71%！新药在肥胖和心血管风险因素患者中的2期研究取得积极结果；SEV转型为公益公司，涨近58%>>
10-24 15:16
Ventyx Stock Is Rallying Thursday: What's Driving The Surge?
Ventyx Biosciences Inc (NASDAQ:VTYX) shares are surging Thursday after the company announced positive Phase 2 study results for VTX3232.
10-24 01:40
What's Driving Beyond Meat's 11% After-Hours Drop?
Beyond Meat shares fell 11% after hours following a volatile rally sparked by ETF inclusion and short-selling activity.
10-23 13:50
Why Ventyx (VTYX) Shares Soared 86.5% After Hours?
Ventyx shares jumped 86.5% in after-hours trading after positive Phase 2 trial results.
10-23 12:34
Ventyx Biosciences shares are trading higher after the company announced results from its Phase 2 study of VTX3232 in participants with obesity and cardiovascular risk factors.
Ventyx Biosciences shares are trading higher after the company announced result...
10-23 04:47
Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors
VTX3232 demonstrated significant reductions in cardiovascular risk factors, including an ~80% reduction in hsCRP and IL-6 levels below the threshold for CV risk. Combining VTX3232 with semaglutide showed additional benefits in reducing inflammation and liver inflammation. VTX3232 was safe and well-tolerated, with adverse events comparable to placebo. The Phase 2 study highlights VTX3232’s potential as a novel oral anti-inflammatory therapy for ca...
10-22 20:02
美股大行评级 | 潜在涨幅162.68%！Ocular Therapeutix获JMP证券升目标价至29美元，维持"跑赢大市"评级
今日重点评级关注：JMP证券：维持Ocular Therapeutix"跑赢大市"评级，目标价从20美元升至29美元；汇丰银行：上调Banco BBVA Argentina评级至"买入"，目标价从21美元下调至17美元
10-02 15:08
